NCT05105100View on ClinicalTrials.gov

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2025

Conditions
MelanomaAdvanced Melanoma
Interventions
PROCEDURE

Biopsy

Tumor tissue collection

PROCEDURE

Biospecimen Collection

Intravenously Blood draw

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT05105100 - Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma | Biotech Hunter | Biotech Hunter